Human Genome Epidemiology Literature Finder
Records 1 - 6 (of 6 Records) |
Query Trace: Gallbladder Neoplasms and EGFR[original query] |
---|
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Jul 28 (21): 3491-7. Lubner Sam J, Mahoney Michelle R, Kolesar Jill L, Loconte Noelle K, Kim George P, Pitot Henry C, Philip Philip A, Picus Joel, Yong Wei-Peng, Horvath Lisa, Van Hazel Guy, Erlichman Charles E, Holen Kyle |
Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients. Ecancermedicalscience 2017 11 757. Sharma Aarti, Kumar Ashok, Kumari Niraj, Krishnani Narendra, Rastogi Neer |
ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. International journal of cancer 2018 Oct . Iyer Prajish, Shrikhande Shailesh V, Ranjan Malika, Joshi Asim, Gardi Nilesh, Prasad Ratnam, Dharavath Bhasker, Thorat Rahul, Salunkhe Sameer, Sahoo Bikram, Chandrani Pratik, Kore Hitesh, Mohanty Bhabani, Chaudhari Vikram, Choughule Anuradha, Kawle Dhananjay, Chaudhari Pradip, Ingle Arvind, Banavali Shripad, Gera Poonam, Ramadwar Mukta R, Prabhash Kumar, Barreto Savio George, Dutt Shilpee, Dutt Am |
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies. Frontiers in oncology 2020 5 10 536. Wang Shuhang, Chen Rongrong, Tang Yu, Yu Yue, Fang Yuan, Huang Huiyao, Wu Dawei, Fang Hong, Bai Ying, Sun Chao, Yu Anqi, Fan Qi, Gu Dejian, Yi Xin, Li Ni |
MAP kinase and mammalian target of rapamycin are main pathways of gallbladder carcinogenesis: results from bioinformatic analysis of next generation sequencing data from a hospital-based cohort (NCT05404347). Molecular biology reports 2022 8 49 (11): 10153-10163. Rajput Monika, Chigurupati Satyavjiay, Purwar Roli, Shukla Mridula, Pandey Man |
Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved. Pathology, research and practice 2022 3 232 153806. Mishra Sridhar, Kumari Swati, Srivastava Pallavi, Pandey Anshuman, Shukla Saumya, Husain Nuzh |
- Page last reviewed:Feb 1, 2024
- Content source: